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To predict the safety of a drug at an early stage in its development is a major challenge as there is a lack of in vitro heart
models that correlate data from preclinical toxicity screening assays with clinical results. A biophysically detailed computer
model of the heart, the virtual heart, provides a powerful tool for simulating drug–ion channel interactions and cardiac
functions during normal and disease conditions and, therefore, provides a powerful platform for drug cardiotoxicity screening.
In this article, we first review recent progress in the development of theory on drug–ion channel interactions and
mathematical modelling. Then we propose a family of biomarkers that can quantitatively characterize the actions of a drug on
the electrical activity of the heart at multi-physical scales including cellular and tissue levels. We also conducted some
simulations to demonstrate the application of the virtual heart to assess the pro-arrhythmic effects of cisapride and
amiodarone. Using the model we investigated the mechanisms responsible for the differences between the two drugs on
pro-arrhythmogenesis, even though both prolong the QT interval of ECGs. Several challenges for further development of a
virtual heart as a platform for screening drug cardiotoxicity are discussed.
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guarded receptor; HH, Hodgkin–Huxley; ICaL, L-type Ca2+ current; IKr, delayed rectifier K+ channel current; IKtof, fast
component of the cardiac transient outward current; INa, Na+ channel current; LQTs, long QT syndrome; MR,














These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://
www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are
permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (a,bAlexander et al., 2013a,b).
BJP British Journal ofPharmacology
DOI:10.1111/bph.12996
www.brjpharmacol.org
British Journal of Pharmacology (2015) 172 5531–5547 5531© 2014 The Authors. British Journal of Pharmacology published by John Wiley &
Sons Ltd on behalf of The British Pharmacological Society.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Introduction
The development of a new drug from its discovery to final
market approval takes, on average, about 10 years and costs
over ∼$1 billion (DiMasi et al., 2003). Some drugs (e.g. cis-
apride) have had to be withdrawn due to their undesirable
side effects, such as cardiotoxicity (Hondeghem et al., 2011).
Withdrawal of a cardiotoxic drug is not just a waste of time
and money for the pharmaceutical industry, but may also
impose serious risks to a patient’s life. Therefore, predicting
the side effects of a drug at an early stage of its development
is of utmost importance as regards drug safety assessments
(Pollard et al., 2010).
One of the most dangerous potential side effects of a drug
is pro-arrhythmic effects arising from an interaction between
drug molecules and cardiac membrane ion channels. A con-
temporary biomarker for predicting a drug’s safety is based on
its effect on the corrected QT interval (QTc) of the ECG
(Friedrichs et al., 2005): a drug that prolongs the QTc is
regarded as having a great potential for triggering severe
pro-arrhythmic events. As the delayed rectifier K+ channel
current (IKr) provides a major repolarizing current that deter-
mines the cellular action potential duration (APD) and, there-
fore, the QT interval of an ECG, testing the effects of a drug
on IKr is normally performed as a preclinical screening to
predict any potential risks of the drug. However, in most
cases, drug-induced arrhythmia risk is not solely due to inhi-
bition of IKr, neither do all drugs that prolong the QTc interval
induce arrhythmia. In fact, drug-induced arrhythmias may
result from complex interactions between a drug and cardiac
electrophysiology, including tissue’s excitability, refractori-
ness and spatial dispersion of ventricular repolarization. In
some cases, where a drug acts (directly or indirectly) on mul-
tiple transmembrane ion channels simultaneously (i.e.
combined actions on K+, Na+ and L-type Ca2+channels)
(Hondeghem et al., 2001; Gintant, 2012), the mechanisms
involved in the pro-arrhythmia effects of a drug are even
more complex. Consequentially, the assessment of a drug’s
safety that is confined to preclinical screening for actions on
IKr or clinical QT interval is unlikely to be ineffective. Hence,
novel methods are required to evaluate the complicated
actions of a drug on cardiac activities for the assessment of
drug cardiotoxicity.
In recent years, there have been rapid advances in the
development of biophysically detailed computer models of
the heart for simulating its electrical and mechanical dynam-
ics (i.e. the virtual heart) (Clayton et al., 2011; Henriquez,
2014). The virtual heart has been extensively implemented as
a cardiac electrophysiological platform for investigating the
functions of the heart during various physiological, pathologi-
cal and pharmaceutical conditions (Clayton et al., 2011;
Henriquez, 2014). Recently, it has attracted attention as an
appliance for quantitatively evaluating drug safety (Mirams
et al., 2012).
In this review, we first present recent progress in the
mathematical modelling of the drug–ion channel interac-
tions in cardiac tissue. We then propose a family of biomark-
ers that can be used to quantitatively characterize the actions
of a drug on cardiac electrical activities at the cellular and
tissue level. To illustrate the suitability of the virtual heart as
a screening strategy, we used computer models of the human
ventricle to simulate and quantify the effects of cisapride and
amiodarone on ventricular activities and pro-arrhythmic sub-
strates. Finally, we discuss several challenges that need to be
considered for the future development of a whole heart
model as a platform for screening drug safety.
Theory for the interaction between
ion channels and drugs
Mathematical models for ion channels
Two approaches have been used for mathematical modelling
of the functions of cardiac membrane ion channels. One is
the Hodgkin–Huxley (HH)-type model (Clayton et al., 2011;
Henriquez, 2014), in which voltage and time-dependent
gating variables are used to describe the properties of an ion
channel, with activation and inactivation processes being
assumed to be independent. For instance, the fast sodium
channel current can be described by (Noble, 1960; 1962; Kohl
and Noble, 2009; Kharche et al., 2011):
I g m hj V ENa Na m rev= −3 ( ) (1)
where INa is the sodium channel current; gNa the maximal
channel conductance; m the voltage- and time-dependent
activation variable; h and j the fast and slow inactivation
variables, respectively; Vm the cell membrane potential; and
Erev the reversal potential of the channel (for model details,
please see Appendix A).
The other is the Markov chain type of ion channel model
that allows for detailed descriptions of the specific channel
states and the transitions between them (Iyer et al., 2004; Rudy
and Silva, 2006; Clancy et al., 2007). Transitions between
states can be dependent on voltage, temperature and drug
concentration. So far, detailed Markov chain models have
been developed for several cardiac membrane ion channels,
including the transient outward K+ current Ito (IKv4.3 and IKv1.4)
(Iyer et al., 2004), INa and IK (IKr and IKs) (Rudy and Silva, 2006).
Theory for a drug’s interaction with
ion channels
Receptor theory is an important framework for mathematical
modelling of pharmacological actions of cardiac ion chan-
nels. With this theory, a receptor model is based on the
known laws of physical chemistry for describing the binding
of drug molecules to cellular receptors, which can be divided
into three categories (Kenakin, 2004) as listed below.
Theory of simple pore block. The ‘simple pore block’ theory
assumes that drug molecules continuously access the ligand-
binding site of the ion channel receptor and the affinity of
the drug molecule for the receptor is independent of time and
cardiac membrane voltage (Starmer et al., 1994). With this
theory, the effects of a drug on blocking an ion channel can
be simulated using a blocking factor k that reduces the
maximum conductance of the targeted ion channel. Math-
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where [D] is the drug concentration, IC50 the drug concentra-
tion at which 50% of blockade of the binding site occurs and
nH the Hill coefficient.
The simple pore block theory has been widely used for
simulating drug action on cardiac electrical activities. For
example, Starmer et al. (1994) implemented the theory to
investigate the mechanism by which a drug blocking potas-
sium channels suppressed the responses of cardiac cells to
premature stimuli. Later on, Starmer et al. (1995) also imple-
mented the theory to investigate the anti-arrhythmic effects
of potassium channel blockade.
Theory of state-dependent block. The ‘state-dependent block’
theory is based on the dynamic properties of ion channels.
There are two subcategories, the modulated receptor (MR)
theory (Hille, 1977) and the guarded receptor (GR) theory
(Starmer et al., 1984).
Both the MR and GR theories assume that the association
and dissociation processes of a drug molecule are dependent
on time and cellular membrane potential. However, the MR
theory proposes that a drug can bind to the drug receptor
regardless of the state of the targeted ion channel, and its
binding affinity in each state is different. In contrast, the GR
theory hypothesized that the affinity of drug binding to a
particular conformation of an ion channel is constant, and
the access of the drug to the binding site is limited due to
alterations in the ion channel conformation.
Based on the MR theory, Hondeghem and Katzung (1977)
proposed an HH type of model for simulating the action of
lidocaine and quinidine on INa. In this model, the Na+
channel model had closed (R), active (A) and inactivated (I)
states, and the drug had the same affinity to block each of
them, as shown in Figure 1A. Thus, a mathematical model for
the INa was represented as:
I g B m hj V ENa Na m rev= −( ) −( )1 3 (3)
dB
dt
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where B is the sum of the blocked Na+ channels, [D] the drug
concentration, ‘i’ the fraction of channels in the three
blocked states, li and ki are the dissociation and association
rates of different Na+ channel states respectively (for details of
the model and parameters, please see Appendix A).
With the GR theory, Starmer and Grant (1985) proposed
an HH type of Na+ channel model, with the effects of a drug
shown in Figure 1B. With B representing the total number of
drug-blocked channels (Starmer and Grant, 1985):
dB
dt
k D B l BA A= [ ] −( ) +1 (5)
where kA and lA are the association and dissociation rates. For
details of this model and parameters, please see Appendix A.
Theory of allosteric effect. The ‘allosteric effector’ (AE) theory
differs from the ‘state-dependent block’ theory in that the AE
theory considers that drugs act as allosteric effectors to alter
the transition dynamics of the targeted ion channels instead
of simply blocking them. A recent study has implemented the
AE theory, together with the MR and GR theories and Markov
chain model of ion channel gating kinetics to illustrate how
class I anti-arrhythmic drugs, lidocaine and flecainide, affect
ventricular rhythms by inducing functional changes in the
dynamics of Na+ channels (Moreno et al., 2011).
Modelling the interactions between
drug and ion channels
Na+ channel and drug interaction
The Na+ channel plays an important role in generating cardiac
electrical action potentials (APs) (i.e. it is a major determinant
of the maximal upstroke velocity of the AP and cardiac excit-
ability) and ensuring AP conduction in the cardiac tissue.
Drugs that target Na+ channels have been widely used for
treating various cardiac diseases (Corrias et al., 2010).
Mathematical modelling of the interaction between the
Na+ channel and drugs can be dated back to 1977 when
Hondeghem and Katzung (1977) pioneered the study to
investigate the anti-arrhythmic properties of the cardiac Na+
channel blockers, lidocaine and quinidine, using the MR
theory. Later on, Starmer et al. (1987; Starmer, 1987) devel-
oped a GR-based model for simulating the actions of lido-
caine on the cardiac Na+ channel and investigated the
mechanisms by which the anaesthetics affect cardiac excit-
ability (Starmer, 1987; Starmer et al., 1987). Recently, using
the same GR-based model, Starmer et al. (2003b) investigated
the effects of Na+ channel blockade on the refractory period
of cardiac excitations.
Models for simulating interactions between drugs and
Markov chain model of Na+ channels have also been devel-
oped. In their study, Clancy et al. (2007) developed a Markov
chain model for the ΔKPQ mutant Na+ channel that is asso-
ciated with variant 3 of long QT syndrome (LQT3). The
model presented the ΔKPQ mutant channel with drug-
binding sites for the open and inactivation states of Na+
channels for simulating the actions of mexiletine and lido-
caine. Recently, Moreno et al. (2013) developed another
Markov chain type of Na+ channel model, with eight states
representing drug bound effects, eight discrete background
states representing the non-affected channel conformations
and another four states describing Na+ channel bursting
Figure 1
Schematic illustration of the modulated receptor theory and guarded
receptor theory on the HH type of Na+ ion channel. Figure adapted
from Comtois et al. (2008). (A) Modulated receptor model proposed
by Hondeghem and Katzung (1977) with transition rates from
unblocked to blocked channels (k) and from blocked to unblocked
(l). (B) Guarded receptor model with affinity to the inactivated and
activated states (Starmer and Grant, 1985).
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(Gima and Rudy, 2002). Modelling studies showed that acute
targeting of INaL by ranolazine effectively suppressed the trig-
gers for bradyarrhythmias in LQT3-linked ΔKPQ mutants or
tachyarrhythmia arising from heart failure (Moreno et al.,
2013). Models incorporating binding/unbinding properties
between drugs and channels that are important in determin-
ing a drug’s safety profile have also been developed
(Cimponeriu et al., 2003).
Potassium channel and drug interaction
The IKr activates during the plateau phase of the AP and plays
an important role in AP repolarization (Sanguinetti and
Tristani-Firouzi, 2006). The KV11.1 (also known as hERG)
channel is considered to be the most widely targeted potas-
sium channel in arrhythmic pharmacological therapy.
Using a previous model of IKr developed by Silva and Rudy
(2005), Sale et al. constructed two Markov chain models for
representing hERG 1a/1b and hERG 1a channels (Sanguinetti
et al., 1995; Trudeau et al., 1995; Smith et al., 1996). Their
modelling results showed that the time course of E-4031 for
blocking heteromeric 1a/1b channels was slower than that for
blocking homomeric 1a channels (Sale et al., 2008), which
suggested that specifically disrupting hERG 1b channel func-
tion was expected to reduce cardiac IKr and enhance drug
sensitivity.
Drug molecular binding to channel states with different
conformations or a distinct affinity presents complex behav-
iours. In a recent study, Romero et al. (2014) investigated in
silico the drug/channel interactions by systematically altering
the transition rates in the Fink et al. (2008) Markov chain
model of human hERG (KV11.1) channels. By incorporating
the drug–channel model into the O’Hara et al. (2011) model
of human ventricular APs, they showed that drugs with dis-
parate affinities to conformational states of the KV11.1
channel played an important role in increasing a tissue’s
susceptibility to acquired LQT. Independently, Di Veroli et al.
(2014) developed a mathematical model of KV11.1 channels
to study drug safety with different binding configurations.
Based on experimental data on the effect of the antipsychotic
clozapine on hERG channel blocking and unblocking kinet-
ics, Hill et al. (2014) proposed an hERG channel model with
kinetically distinct binding states of the drug to open and
inactivation states. Their modelling data effectively illus-
trated the interaction between clozapine and hERG channels
in acquired LQT (Hill et al., 2014).
The fast component of the cardiac transient outward
current, IKtof, plays an important role in the early phase of
repolarization. A Markov chain type of formulation of IKtof
with consideration of the effects of different IKtof-specific block
states (drug bound to the three closed states and the open
state of IKtof) on mouse ventricular APD has also been devel-
oped (Zhou et al., 2012).
Calcium channel and drug interactions
L-type Ca2+ channels constitute a main Ca2+ entry pathway
into the cell and play an important role in cardiac excitation
(Corrias et al., 2010). Pharmacological therapies targeting the
cardiac ICaL have also been widely considered in practice.
Markov chain models for representing the ICaL have also
been developed in previous studies (Hund and Rudy, 2004).
These models have been implemented to investigate the effect
of β-adrenoceptor stimulation on ventricular arrhythmogen-
esis in association with LQT (Faber and Rudy, 2007; Faber et al.,
2007).
Multichannel and drug interactions
Drugs targeting multiple membrane ion channels may be
effectively anti-arrhythmic. Computer modelling provides a
tool for theoretically exploring the actions of a drug targeting
multiple ion channels (Martin et al., 2004; Qu and Weiss,
2005; Bottino et al., 2006). It has been shown by a simulation
study that a putative compound that blocks the three
ion channels, which mediate IKr, INa, ICaL, had better anti-
arrhythmic effects than one that only blocks the IKr (Mirams
et al., 2011).
Some other advances in simulation of the interaction
between a drug and the various ion channels are summarized
in Appendix B.
Assessment flow for the action of a
drug in silico
The electrical activity of the heart results from the coordi-
nated actions of cardiac systems operating at many physi-
ological sites, including subcellular, ion channel, cellular,
tissue and organ levels. Therefore, a comprehensive assess-
ment of drug safety has to be conducted at all of these levels.
This imposes a major challenge, if not impossible, for con-
ventional experimental preclinical drug safety screening.
However, it can be achieved by computer models of the heart.
In this regard, we propose an assessment flow for evaluating
the actions of a drug at the cellular and tissue levels using
computer models of the heart as illustrated in Figure 2.
In the following section, as illustrated, we present simula-
tion results to demonstrate the application of computer
models for evaluating the actions of cisapride and amiodarone
on cardiac electrical activities at the cellular and tissue levels.
Computational evaluation of the
effects of cisapride and amiodarone
Cisapride and amiodarone are both known to prolong the QT
interval of the ECG, yet they have different effects on cardiac
arrhythmogenesis. Cisapride, an IKr blocker, has been with-
drawn from the market due to the high risk for it to induce
torsades de pointes leading to fatal cardiac arrhythmias.
However, amiodarone, a multichannel blocker that simulta-
neously affects the channels that mediate IKr and ICaL, has been
found to be effectively safe and anti-arrhythmic. It is unclear
why the two drugs, while both increasing QT interval, have
different actions on arrhythmogenesis. In this section, we used
a biophysically detailed computational model of the heart to
investigate the effects of the two drugs on the characteristics of
cardiac electrical activities at the cellular and tissue levels.
Single-cell simulations of cisapride
and amiodarone
Choice of single-cell AP model. The well-established ten
Tusscher and Panfilov (2006a) models of the human ventricu-
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lar APs were chosen in this study as they have been well
validated to simulate electrical APs of human ventricular
endo-, middle- and epicardial cells.
Modelling drug–channel interaction. To simulate the actions of
cisapride and amiodarone, we implemented the simple pore
block theory, by which the maximal channel conductance of
the targeted channel(s) was reduced by various percentages
according to the dose of the drug (Table 1). For cisapride, the
channel conductance of IKr was reduced to 70 and 60% of its
original values in control condition for a low (150 nM) and a
high dose (300 nM) respectively (Wilhelms et al., 2012). For
the amiodarone case, the channel conductances of IKr and ICaL
were reduced to 43 and 85%, respectively, for a low dose
(presumably 1 μM), and to 15 and 66% for a high dose (pre-
sumably 3 μM) based on experimental data (Nishimura et al.,
1989; Kodama et al., 1999).
Effects on cellular APs. Figure 3 shows the simulated effects of
cisapride (Figure 3Ai,Bi) and amiodarone (Figure 3Aii,Bii) on
human epicardial ventricular APs at low (left panels) and
high doses (right panels). Simulation suggested that both
drugs did not markedly affect the AP amplitude, resting
potential or dV/dtmax, but both prolonged the APD at 90%
repolarization (APD90). This latter effect on the APD was dose-
dependent. At low doses, cisapride and amiodarone pro-
longed the epicardial APD90 by 12 and 13 ms, respectively,
which was changed to 16 and 11 ms at high doses. Such a
dose-dependent APD prolongation is consistent with the
Figure 2
Assessment flow chart for testing drug actions using hierarchical levels of computer models including ion channel, cellular and tissue levels. The
actions of a drug on cardiac electrical activity at cellular and tissue levels can be characterized by analysing their effects on a family of biomarkers.
Table 1
Scaled ion channel conductance due to actions of cisapride and















GKr 70 60 43 15
GCaL 100 100 85 66ss
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clinically observed increase in the QT interval induced by the
two drugs.
There are no experimental data from human ventricular
cells with which to compare our simulation data. However,
our simulation results are qualitatively comparable with
experimental data obtained from other species. For cisapride,
the simulated APD prolongation was in fair agreement
with experimental observations from canine (Di Diego et al.,
2003) and from rabbit (Varro et al., 1996; Nakagawa et al.,
2010) ventricular cells. Experimentally, it was found that
0.2 μM,cisapride prolonged the canine epicardial APD90
by 9.45 ± 6.4% at a basic cycle length (BCL) of 500 ms
(Figure 3Ci). Our simulation (Figure 3Ci) showed that a low
dose (0.15 μM) and a high dose (0.3 μM) prolonged the APD90
by 3.88 and 5.18%, respectively, which were close to the
experimental data. Quantitative differences between the
simulation and experimental data may reflect species differ-
ences between the human and canine or the rabbit hearts.
The observed dose-dependent APD prolongation is also con-
sistent with the experimental data of Fossa et al. (2004) from
the guinea pig heart.
For amiodarone, experimental data from rabbit epicardial
ventricular cells showed that 5 μM amiodarone prolonged
the APD by 6.63 ± 2.76% at a BCL of 400 ms (Nakagawa et al.,
2010). This is also close to our simulation data of 4.20 and
3.56% for low (1 μM) and high dose (3 μM) respectively
(Figure 3Cii). In simulation, we observed that the APD pro-
longation decreased with an increased dose of amiodarone,
which is consistent with the experimental data of Wu et al.
(2008) from the rabbit heart.
Simulation using the other two types of cell models (i.e.
the middle and endocardial cell models) showed qualitatively
similar results to the epicardial cell model. Results are sum-
marized in Table 2.
Simulation results showed that there were subtle
differences between the two drugs with regard to their
dose-dependent actions on APD. For cisapride, the APD pro-
longation increased with an increased dose. But for the amio-
darone, the APD prolongation decreased with an increased
dose. Such different dose-dependent actions of the two drugs
on APD prolongation may be attributable to the different ion
channels that they target: cisapride only inhibited IKr whereas
amiodarone inhibited both IKr and ICaL. In order to test this
hypothesis and investigate the functional effects of blocking
ICaL, further simulations were performed with different per-
centages of ICaL blocking (10–70%), together with basal block-
ing of IKr by cisapride at low (by 30%) and high (by 40%)
doses (Figure 3Ai,Bi), and basal blocking of IKr by amiodarone
at low (by 57%) and high (by 85%) doses (Figure 3Aii,Bii).
(Hereafter, simulations were also performed for characterizing
the effects of the combined block of IKr and ICaL on other
characteristics of cardiac electrical activities.) It was shown
that blocking IKr alone prolonged the APD. However, when
both IKr and ICaL were blocked, the APD was prolonged when
Figure 3
Simulation of actions of cisapride and amiodarone on human epicardial ventricular APs with comparison to experimental data. Effects of a
combined action of blocking of IKr by the two drugs at high and low doses together with different blocking of ICaL (from 10 to 70%) were also
shown. (Ai, Aii) Actions of cisapride and amiodarone at low doses. (Bi, Bii) Actions of cisapride and amiodarone at high doses. (Ci, Cii) Comparison
of simulated APD prolongation results to experimental data for cisapride (Di Diego et al., 2003) and amiodarone (Nakagawa et al., 2010).
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a low percentage of ICaL was blocked but shortened when a
high percentage of ICaL was blocked. These simulation results
explain why a high dose of amiodarone produces a smaller
APD prolongation as compared with a low dose.
Effects on APD and ERP restitution curves. Measuring the
action of a drug on the APD and effective refractory period
(ERP) restitution curve can help to understand the rate-
dependent actions of the drug on cellular APD and ERP,
which form important biomarkers for characterizing the
effects of a drug. To compute the APD restitution and
ERP curves, we followed the same methods as used in our
previous studies (Zhang and Hancox, 2004; Zhang et al.,
2008).
Figure 4 shows APD restitution curves computed from
epicardial cells at control and low and high doses of cisapride
Table 2
Effects of cisapride and amiodarone on the cellular characteristics (i.e. biomarkers) of human ventricular endocardial, middle and epicardial cells
Endo M Epi
APA dV/dtmax APD90 ΔAPD APA dV/dtmax APD90 ΔAPD APA dV/dtmax APD90 ΔAPD
(mV) (mV·ms−1) (mV) (ms) (ms) (mV·ms−1) (ms) (ms) (mV) (mV·ms−1) (ms) (ms)
Control 129 396 348 – 128 396 402 – 128 397 309 –
Low cisapride 129 396 363 15 128 396 425 23 128 396 321 12
High cisapride 129 396 369 21 128 397 433 31 128 396 325 16
Low amiodarone 129 400 365 17 128 399 430 28 128 400 322 13
High amiodarone 130 405 365 17 129 404 434 32 129 405 320 11
ΔAPD is equal to the difference between the APD90 of control condition and that of a drug dose action in the same cell type.
Figure 4
APD restitution curves computed from the epicardial cell model in the control condition and actions of low and high doses of cisapride and
amiodarone. Effects of a combined block of IKr by the two drugs at high and low doses together with the different blocking of ICaL (from 10 to
70%) are also shown. (A) low dose of cisapride; (B) high dose of cisapride; (C) low dose of amiodarone; (D) high dose of amiodarone.
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(Figure 4A,B) and amiodarone (Figure 4C,D). In comparison
with the control, cisapride and amiodarone prolonged the
APD90 for all the stimulus intervals tested (400–2000 ms),
producing steeper APD restitution curves as shown by
increased maximal slopes of the curves. This suggested an
increased propensity of the two drugs for generating AP alter-
nans leading to arrhythmogenesis (Karagueuzian et al., 2013).
In comparison with amiodarone, the cisapride APD restitu-
tion curves were steeper, illustrating an even higher propen-
sity for the induction of alternans. With regard to the
combined action of ICaL blocking together with the basal
blocking of IKr by the two drugs, APD restitution curves
became flatter with an increased level of ICaL block. This sug-
gested that a drug such as amiodarone (which has a com-
bined action on ICaL and IKr) is superior to a drug such as
cisapride that only blocks IKr for suppressing the development
of AP alternans, a predisposing factor for arrhythmogenesis.
Simulation data also showed that both cisapride and
amiodarone prolonged ERPs for all the considered range of
BCL (200–2000 ms) (data not shown).
Multicellular tissue simulations of cisapride
and amiodarone
Transmural ventricular tissue model. A multicellular model of
transmural ventricular tissue was constructed by incorporat-
ing the ten Tusscher and Panfilov (2006a) model into a reac-
tion diffusion partial differential equation as in our previous
studies (Zhang and Hancox, 2004; Zhang et al., 2008). The
model was used to quantify the actions of cisapride and
amiodarone on cardiac conduction and its vulnerability to
arrhythmogenesis.
Effects on conduction velocity (CV) restitution. At the multicel-
lular tissue level, an important biomarker for characterizing
the actions of a drug on cardiac excitation wave propaga-
tion is the CV and its rate dependence, that is, the CV res-
titution curve (CVRC). Figure 5 show the results of the
computed CVRC in control and cisapride and amiodarone
conditions. It was shown that at low pacing rates with a
BCL greater than 600 ms, neither cisapride (Figure 5A,B) nor
amiodarone (Figure 5C,D) had any noticeable effects on the
measured CV, either at low or high doses. However, at high
pacing rates with a BCL smaller than 600 ms, the two drugs
decreased the CV. The decreased CV at high pacing rates
was attributable to reduced tissue excitability due to
increased ERP.
Blocking ICaL in addition to the basal block of IKr by the
two drugs resulted in a slight decrease in the CV at low pacing
rates, but a marked increase in the CV at high pacing rates
as compared with conditions when only the basal IKr was
blocked.
Effects on excitation wavelength (WL). The excitation WL is
another biomarker to characterize the action of a drug on
cardiac excitation waves. A drug that increases the WL is
believed to be anti-arrhythmic, whereas a drug that shortens
the WL is regarded as being pro-arrhythmic as it allows
limited cardiac tissue to accommodate multiple wavelets of
excitation waves underlying fibrillations.
Figure 6 shows the computed wavelength restitution
curve from the epicardial cell model in control and cisapride
(Figure 6A,B) and amiodarone (Figure 6C,D) conditions at
low and high doses. In contrast to the CV (Figure 5), the WL
Figure 5
Computed effects of cisapride and amiodarone on conduction velocity restitution curves of cardiac excitation waves at low and high doses. Effects
of a combined action of blocking of IKr by the two drugs at high and low doses together with different blocking of ICaL (from 10 to 70%) are also shown.
(A) low dose of cisapride; (B) high dose of cisapride; (C) low dose of amiodarone; (D) high dose of amiodarone.
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measured was always greater under cisapride and amiodarone
conditions, regardless of the pacing BCL.
Blocking ICaL in addition to basal blocking of IKr by the two
drugs resulted in a decreased WL as compared with when
only basal IKr was blocked.
Effects on tissue vulnerability for arrhythmogenesis. Vulnerabil-
ity of cardiac tissue to generate unidirectional conduction
block in response to a premature stimulus provides another
important biomarker to characterize the actions of a drug. In
simulations, the vulnerability of cardiac tissues was quanti-
fied by the width of a time window [vulnerable window
(VW)] during which a test stimulus applied to a refractory tail
of a previous excitation wave to evoke unidirectional conduc-
tion. A tissue’s vulnerability was measured by the same
method as used in our previous studies (Zhang and Hancox,
2004; Zhang et al., 2008). The width of the VW measures
the vulnerability of the tissue for arrhythmogenesis. The
greater the width of the VW, the higher the propensity for
arrhythmogenesis.
Figure 7 shows th ecomputed width of the VW under
control and cisapride and amiodarone conditions (Figure 7A).
In the control condition, the VW was 14.3 ms. In the cis-
apride condition, the WL was increased to 15.2 and 15.7 ms
for low and high dose respectively. For the amiodarone
condition, the VW was about 15 ms for both low and high
doses.
As compared with the cisapride condition, the measured
VW in the amiodarone condition was smaller, suggesting a less
pro-arrhythmic effect of amiodarone. Furthermore, the meas-
ured VW remained almost constant at low and high dose of
amiodarone, rather than in the case of cisapride, where the
measured VW was greater at high doses than at low doses. A
smaller VW of amiodarone may be attributable to its com-
bined action on both IKr and ICaL. To test this hypothesis,
further simulations were performed with a basal 30% block of
IKr by a low dose of cisapride, together with a 10 and 30% block
of ICaL. The results are shown in Figure 7B. The combined
action of blocking IKr and ICaL reduced the measured VW (14.3
and 13.7 ms for 10 and 30% blocking ICaL, respectively), sug-
gesting a reduced propensity of cardiac tissue for arrhythmo-
genesis. With 30% of both IKr and ICaL blocked, the measured
VW was smaller than that in the control condition (13.7 vs.
14.3 ms), highlighting the superiority of a drug targeting both
Figure 6
Computed wavelength restitution curves of cardiac excitation waves in control and cisapride and amiodarone conditions. Effects of a combined
action of blocking of IKr by the two drugs at high and low doses together with different blocking of ICaL (from 10% to 70%) are also shown.
(A) low dose of cisapride; (B) high dose of cisapride; (C) low dose of amiodarone; (D) high dose of amiodarone.
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IKr and ICaL compared to one targeting IKr only. These results
provide insights into understanding why amiodarone is less
likely to have pro-arrhythmic effects than cisapride.
Effects on ECG. Effect of a drug on the QT interval of ECG
has been used as an index to characterize the safety of the
drug in practice. The effects of a drug on the characteristics of
a pseudo-ECG can also be computed in the model. In simu-
lations, the pseudo-ECG was computed as an integral of
spatial gradient of membrane potential at all positions on the
strand from a virtual electrode located in the extracellular
space following the methods used by other studies (Gima and
Rudy, 2002; Zhang and Hancox, 2004).
Figure 8 shows the results of simulated ECGs under
control and cisapride and amiodarone conditions at low and
high doses (Figure 8, left panel). It was shown that both
cisapride and amiodarone prolonged the QT interval of ECG.
Amiodarone increased the amplitude of the T wave at a low
dose, but such an increased T-wave amplitude became insig-
nificant at a high dose. Cisapride did not show any noticeable
effects on the T-wave amplitude. In simulations, cisapride
prolonged the QT interval by 7.50 and 8.75% for low and
high dose, respectively (Figure 8, right panel), which was in
fair agreement with experimental data that showed a 8.74 ±
5.28% prolongation in the QT interval by 0.2 μM cisapride in
the canine heart (Di Diego et al., 2003); amiodarone at low
Figure 7
(A) Computed width of vulnerable window of cardiac tissue in control and cisapride and amiodarone conditions. (B) Comparison of vulnerable
window for cisapride at a low dose, basal IKr blocking (by 30%) of cisapride together with additional blocking of ICaL by 10 and 30%.
Figure 8
(Left panel) Computed pseudo-ECG in control and cisapride and amiodarone conditions. Both drugs prolonged QT interval. (Right panel)
Comparison of simulated QT interval prolongation to experimental data for cisapride (Di Diego et al., 2003) and amiodarone (Varro et al., 1996).
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and high doses prolonged the QT interval by 10.94 and
12.81%, respectively, which was also fairly close to the 24.63
± 6.72% QT interval prolongation by 5 μM amiodarone in the
rabbit (Varro et al., 1996).
Effects on initiation and maintenance of re-entrant excitation
waves. Re-entrant excitation waves are believed to be asso-
ciated with cardiac tachycardial arrhythmias or fibrillation.
Further simulations were performed to investigate the effects
of cisapride and amiodarone on the initiation and mainte-
nance of re-entrant excitation waves in a three-dimensional
realistic model of human ventricles developed in our previ-
ous studies (Adeniran et al., 2011). In order to evaluate the
effects of cisapride and amiodarone on re-entry initiation and
maintenance, the lifespan of the re-entry and power spec-
trum of electrical activity recorded from a local site of the
ventricle were computed.
The results are shown in Figure 9 for control (Figure 9Ai–
Aiii), and high doses of cisapride (Figure 9Bi–Biii) and amio-
darone (Figure 9Ci–Ciii). In the control case, re-entry was
initiated and sustained as shown by the snapshots of excita-
tion pattern in the ventricle (Figure 9Ai). The electrical
activity recorded showed rapid spontaneous ventricular exci-
tation (Figure 9Aii) with a dominant frequency of 4.84 Hz
(Figure 9Aiii). With the high dose of cisapride, re-entry was
also initiated and sustained (Figure 9Bi), with rapid sponta-
neous ventricular electrical activity (Figure 9Bii), but the
excitation was slowed down with a dominant frequency
of 4.17 Hz as compared with the control condition
(Figure 9Biii). However, with the high dose of amiodarone,
re-entry was self-terminated shortly after initiation
(Figure 9Ci–Ciii). Consistent with the actions of these two
drug effects on arrhythmogenic effects elucidated at the cel-
lular and tissue levels, at the three-dimensional organ level,
cisapride increased susceptibility to initiation and mainte-
nance of re-entry, but amiodarone, by terminating re-entry,
was anti-arrhythmic.
Discussion
Biophysically detailed and well-validated computer models of
the heart have shown excellent promise as an alternative
preclinical cardiotoxicity screening tool. Since the pioneering
work of Denis Noble (1960), many complex and precise
cardiac cell models have been developed in the last few
decades for various species and different cell types, which
form a fundamental basis for the virtual physiological heart
(Kohl and Noble, 2009; Clayton et al., 2011). The virtual
heart has attracted increasing attention for its application in
drug development and assessment (Xie et al., 2014). With the
use of the virtual heart, the effects of a drug on cardiac
electrical activities can be quantitatively characterized at dif-
ferent levels, thus providing a better assessment of the safety
profile of a drug as compared with the conventional use of QT
prolongation or effects on IKr.
Mechanistic insights into the actions of
cisapride and amiodarone
Our simulation results showed that cisapride, an hERG
channel blocker, prolonged cellular APD, steepened the APD
and ERP restitution cures, increased a tissue’s vulnerability to
arrhythmogenesis and sustained but slowed down re-entrant
excitation waves. However, although amiodarone, a com-
bined channel blocker of hERG and L-type Ca2+ channels,
also prolonged cellular APD, it steepened the APD and ERP
restitution curves to a lesser degree, reduced the tissue’s vul-
nerability to arrhythmogenesis and most importantly termi-
nated re-entrant excitation waves as compared with cisapride.
These data explain why amiodarone is safer than cisapride as
an anti-arrhythmic treatment. Furthermore, our simulations
showed that such a difference in the two drugs can be
Figure 9
Initiation and maintenance of re-entry in a three-dimensional realistic
model of human ventricles under control (A), high cisapride (B),
amiodarone (C) conditions. (Ai, Bi, Ci) Snapshots of conduction
pattern of ventricular re-entry. (Aii, Bii, Cii) Time series of electrical
activity recorded from a local site in the ventricle. (Ci, Cii, Ciii) Power
spectrum of the recorded electrical activities.
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attributable to the blocking effect of amiodarone on ICaL in
addition to the blocking of IKr.
Future challenges
Although advances have been made in the last few decades in
modelling drug–channel interactions and cardiac electro-
physiology, there are still some challenges ahead for imple-
menting the virtual heart model for drug safety assessment.
Firstly, more studies are needed to develop biophysically
accurate models for simulating the interactions between drug
molecules and ion channel receptors. This requires not only
further development of theories on the interaction between
drug and channel(s) but also detailed experimental data on
the kinetics of a drug’s actions. A complete set of such experi-
mental data will help to derive and validate mathematical
equations and parameters for the drug–channel interaction
model. Secondly, well-validated models for simulating differ-
ent cell types of the human heart in normal physiological
and various pathological conditions are needed. A complete
set of these cell models can be incorporated into the whole
heart model for simulating the actions of the drug on the
electrical activities of the whole heart conduction system, not
just in a localized region of the heart such as the ventricle.
This whole heart model can be used to answer questions such
as ‘is a drug that is effective for anti-ventricular fibrillation
safe for atrioventricular node conduction?’ Thirdly, cardiac
arrhythmogenesis is associated with autonomic modulations,
and so are the drug-induced cardiac arrhythmias. Therefore,
it is necessary to incorporate the actions of autonomic regu-
lations on the cardiac models for simulating the actions of
drugs and their interactions with the heart during changes in
autonomic systems. In addition, recently there are some new
developments in structure-based virtual drug screening
(Villoutreix et al., 2008), as well as simulations of drug–ion
channel interactions based on protein structures (Silva et al.,
2009; Silva and Rudy, 2010; Nekouzadeh and Rudy, 2011).
How to incorporate such microscale models into a large-scale
whole heart model for simulating and evaluating the actions
of a drug is also a challenge.
Conclusion
A biophysically accurate, detailed and well-validated model
of the heart provides a powerful platform for quantitative
assessment of a drug’s safety. The platform integrates inde-
pendent and distinct physical results from toxicological
experiments, such as assay and patch clamp data, into a
whole heart model based on detailed data from cellular elec-
trophysiology, electro-anatomical mapping and MRI/CT
structural imaging. The whole heart model can be further
integrated into a three-dimensional human torso model,
forming a multiscale physical platform allowing one to simu-
late the action of a drug on body surface ECGs (as shown in
Figure 10). With these computational tools, the functional
effects of a drug can be thoroughly analysed at the cellular,
tissue and organ levels by a family of corresponding cardiac
electrophysiological properties (i.e. biomarkers), from which
the safety of the drug can be fully assessed.
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Appendices
Appendix A: Details of mathematical
equation of INa in HH and Markovian
chain formats
In the HH format, INa model is based on the Luo and Rudy
(1994b) model, which is given by:
I g m hj V E g nS pFNa Na Na Na= −( ) =3 7 8, . (A1)
ENa RT F Na Nao i= ( ) ⋅ [ ] [ ]( )+ +ln (A2)
For V ≥ −40 mV:
α αh j= = 0 0. (A3)
βh V= + +( ) −[ ]{ }( )1 0 13 1 10 66 11 1. exp . . (A4)
β j V V= ⋅ − ×( ) + +[ ]{ }−0 13 2 535 10 1 327. exp . exp (A5)
For V < −40 mV:
αh V= ⋅ +( ) −[ ]0 135 80 6 8. exp . (A6)




= − × ⋅ ( )[
− × ⋅ −( )]⋅
+
−
1 2714 10 0 2444






7 78 1 0 311 79 23. exp . .( ) + [ ]⋅ +( ){ }V
(A8)
β j V V= ⋅ −( ) + − +( )[ ]{ }0 1212 0 01052 1 0 1378 40 14. exp . exp . .
(A9)
αm V V= +( ) − − +( )[ ]{ }0 32 47 13 1 0 1 47 13. . exp . . (A10)
βm V= ⋅ −( )0 08 11. exp (A11)
In the Markovian chain format, the Na+ channel is based on
the three states of the Na+ channel: resting (R), activated (A)
and inactivated (I).
MR representation of state-dependent drug action
The sum of blocked channels (B) is given by the following:
B R A I= ′ + ′ + ′ (A12)
A hj= m3 (A13)
′ =A hjm3 (A14)
R hj A= − (A15)
′ = − ′R hj A (A16)
I = − −1 B hj (A17)
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Guarded receptor representation of drug action
The model was proposed by Starmer et al. (1991b), with
details as the following:
dB
dt
k D m hj B B l e BA A A I A A= [ ] − −( ) − −3 0 0391 . (A19)
dB
dt
k D m hj B B l e BI I O I I I= [ ] − −( ) − −3 0 0391 . (A20)
I g m hj V ENa Na Na= −( )3 (A21)
I g B B m hj V ENa Na A I Na= − −( ) −( )1 3 (A22)
Simulations of lidocaine action were obtained with a binding
rate kA = 1370.0 ms−1 · M−1 and an unbinding rate lA = 1.3 ×
10−5 ms−1 for the open state and a binding rate kI = 60 ms−1 · M−1
and an unbinding rate lI = 2.3 × 10−4 ms−1 for the inactivated
state.
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Appendix B: List of some advances in simulation of ion channel–drug interactions
Table B1
Major models for simulating drug screening
Model







(Starmer et al., 1994; Starobin et al., 1996)
The Beeler–Reuter model
(Beeler and Reuter, 1977)
INa channel (Starmer et al., 1991a; 2003a,b)
The Ebihara–Johnson model
(Ebihara and Johnson, 1980)
INa channel (Starmer et al., 2003a,b)
The Luo–Rudy model




(Clancy and Rudy, 2002; Cimponeriu et al., 2003; Kapela et al.,
2005; Terrenoire et al., 2005; Trenor et al., 2005; Clancy et al.,
2007; Ahrens-Nicklas et al., 2009; Saiz et al., 2011)
The Ramirez–Nattel-Courtemanche model




(Kneller et al., 2005; Tsujimae et al., 2007; Comtois et al., 2008;
Aguilar-Shardonofsky et al., 2012; Colman et al., 2014)
The Shannon–Bers model
(Shannon et al., 2004)
INa channel (Wu et al., 2011)
The Hund–Rudy model
(Hund and Rudy, 2004)
INa channel (Cardona et al., 2010; Aguilar-Shardonofsky et al., 2012)
The Tusscher model




(Fredj et al., 2006; Sale et al., 2008; Mirams et al., 2011)
The ten Tusscher–Panfilov model
(ten Tusscher and Panfilov, 2006b)
IK channel (Dux-Santoy et al., 2011)
The O’Hara–Rudy model
(O’Hara et al., 2011)
INa channel
IK channel
(Moreno et al., 2013)
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